FDA Grants Arrowhead (ARWR) Clearance to Initiate Adipotide Phase I Clinical Trial
Arrowhead Research Corporation (NASDAQ: ARWR) today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound. Adipotide specifically targets and kills blood vessels supplying white fat tissue. The Phase I clinical trial will be conducted by The University of Texas MD Anderson Cancer Center, which will bear the costs of the planned clinical trial.
“This is a significant milestone for our rapidly moving obesity program,” said Dr. Christopher Anzalone, President and Chief Executive Officer. “Less than two months ago, data demonstrating substantial weight loss in obese rhesus monkeys using AdipotideTM was published in the prominent peer-reviewed journal, Science Translational Medicine. We are very excited to take this next step and that MD Anderson plans to start treating patients shortly. We believe we have a powerful suite of drug candidates that not only may help to combat obesity, but also may help to reverse symptoms associated with Type II Diabetes.”
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
“This is a significant milestone for our rapidly moving obesity program,” said Dr. Christopher Anzalone, President and Chief Executive Officer. “Less than two months ago, data demonstrating substantial weight loss in obese rhesus monkeys using AdipotideTM was published in the prominent peer-reviewed journal, Science Translational Medicine. We are very excited to take this next step and that MD Anderson plans to start treating patients shortly. We believe we have a powerful suite of drug candidates that not only may help to combat obesity, but also may help to reverse symptoms associated with Type II Diabetes.”
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Arrowhead Presents Data on DPC System at TIDES 2012
- AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
